About collegium pharmaceutical inc - COLL
Collegium Pharmaceutical, Inc. is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. The firm has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
COLL At a Glance
Collegium Pharmaceutical, Inc.
100 Technology Center Drive
Stoughton, Massachusetts 02072
| Phone | 1-781-713-3699 | Revenue | 780.57M | |
| Industry | Pharmaceuticals: Major | Net Income | 62.87M | |
| Sector | Health Technology | 2025 Sales Growth | 23.615% | |
| Fiscal Year-end | 12 / 2026 | Employees | 423 | |
| View SEC Filings |
COLL Valuation
| P/E Current | 19.201 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 26.687 |
| Price to Sales Ratio | 2.355 |
| Price to Book Ratio | 4.866 |
| Price to Cash Flow Ratio | 5.58 |
| Enterprise Value to EBITDA | 5.732 |
| Enterprise Value to Sales | 3.034 |
| Total Debt to Enterprise Value | 0.395 |
COLL Efficiency
| Revenue/Employee | 1,845,312.057 |
| Income Per Employee | 148,628.842 |
| Receivables Turnover | 3.694 |
| Total Asset Turnover | 0.466 |
COLL Liquidity
| Current Ratio | 1.571 |
| Quick Ratio | 1.478 |
| Cash Ratio | 0.924 |
COLL Profitability
| Gross Margin | 59.349 |
| Operating Margin | 23.968 |
| Pretax Margin | 11.866 |
| Net Margin | 8.054 |
| Return on Assets | 3.754 |
| Return on Equity | 23.701 |
| Return on Total Capital | 5.078 |
| Return on Invested Capital | 5.349 |
COLL Capital Structure
| Total Debt to Total Equity | 310.409 |
| Total Debt to Total Capital | 75.634 |
| Total Debt to Total Assets | 55.542 |
| Long-Term Debt to Equity | 300.33 |
| Long-Term Debt to Total Capital | 73.178 |